M3 Group extends reach in Iberian and Latin American markets with partnership

Share this article:
Aki Tomaru
Aki Tomaru

MDLinx owner M3 Group is partnering with Argentine online CME firm Medcenter on a content-sharing deal that will expand its in-language reach to Spain, Portugal and Latin America.

Medcenter will join M3's Networks in Health, an “international alliance of online physician communities that provides pharmaceutical, medical device and other healthcare companies services for reaching and engaging doctors across Europe, the Americas and Asia.”

“We're trying to be global,” said Aki Tomaru, CEO of M3 USA. Tomaru said that while M3's Doctors.net.uk runs pan-European campaigns, pharmas are increasingly shopping for broader buys that hopscotch across global markets.

“They want to cherry-pick the countries,” said Tomaru. Until now, he added, that meant either partnering with a different in-culture shop in each country or distributing their content in English through WebMD's Medscape (with which Medcenter had a previous affiliation). “The willingness of most physicians in non-English-speaking countries to spend time on English language materials is limited,” said Tomaru.

Medcenter boasts a network of 480,000 physicians. M3, a Sony-owned Japanese conglomerate whose portfolio includes M3.com in Japan, US-based MDLinx and UK-based Doctors.net.uk, claims more than a million physician members worldwide.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...